Sol-Gel Technologies Ltd. — Cyborg Score 4/10

Strategic Profile

Sol-Gel markets two approved products: Twyneo (once-daily topical cream for acne vulgaris) and Epsolay (once-daily topical cream for papulopustular rosacea). The clinical pipeline includes SGT-610 in Phase 3 trials for Gorlin Syndrome and SGT-210 (which completed Phase I clinical trial) for rare hyperkeratinization disorders. In March 2026, the company completed an oversubscribed offering of 459,112 shares at $72.00 per share, generating $33.1 million in gross proceeds to fund continued development of SGT-610 and R&D activities.

Cyborg Score Rationale

Sol-Gel operates in a competitive dermatology segment with two commercialized products but faces revenue headwinds—Q1 2026 revenue fell to $0.1 million from $1.0 million in Q1 2025. The company has substantial cash from recent financing and a focused late-stage pipeline, but execution risk remains high as the company scales SGT-610 development and commercialization.

Top Insights

• Recently completed $33.1M equity raise (March 2026) demonstrates investor confidence in SGT-610 potential despite Q1 2026 revenue decline
• Dual asset strategy: two commercial-stage products (Twyneo, Epsolay) + high-risk/high-reward Phase 3 program (SGT-610 for rare Gorlin syndrome)
• Proprietary microencapsulation platform differentiates topical formulations but requires sustained clinical validation to drive revenue growth
• Collaboration and licensing partnerships with Galderma and Searchlight Pharma extend market reach but create revenue dependency on partner execution

Named Competitors

• Galderma Products — Leading topical dermatology and aesthetic treatments
• Dermatology Portfolio — Diversified eye and skin health products
• Topical Dermatologics — Specialized topical dermatology treatments

Recent Developments

• (March 2026) Completed oversubscribed public offering of $33.1 million in gross proceeds at $72.00 per share
• (Q1 2026) Filed annual Form 20-F for fiscal year ended December 31, 2025
• (Q1 2026) Reported revenue of $0.1 million, down from $1.0 million in Q1 2025

Open the full interactive Sol-Gel Technologies Ltd. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.